A research fund dedicated to fighting Leiomyosarcoma
Join us in pioneering precision medicine to change lives.
Leiomyosarcoma (LMS) is a rare and underfunded sarcoma affecting 1,000 people annually in the UK. Sarcomas are a group of more than 100 different rare cancers affecting connective tissue such as muscle, blood vessles and fat.
2%
Fewer than 2% of cancers are sarcomas
20%
LMS represents about 20% of soft tissue sarcomas in the UK
55/45
LMS predominantly affects women, 55 cases out of 100
A community of experts
LMS Research Fund was founded in London in 2023 by Tim Dye and Charlotte Ransom and is the result of 8 years’ work to understand how best to support research to improve outcomes for patients with rare cancers and LMS specifically.
Working very closely with an expert team of oncologists and immunologists, our approach is very hands on.
Our Research Projects
LMS Research Fund has initiated three specific research projects that we expect to contribute to improving outcomes for LMS patients worldwide.